Dexamethasone in Tick-borne Encephalitis

Treatment With Dexamethasone in Patients With Tick-borne Encephalitis: Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07584525

Enrollment

200

Registered

2026-05-13

Start date

2024-05-03

Completion date

2030-09-30

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tick-Borne Encephalitis

Brief summary

The purpose of this study is to investigate the efficacy of dexamethasone in patients with tick-borne encephalitis.

Interventions

DRUGDexametasone

dexamethasone 4 mg tid

DRUGSaline (0.9% NaCl)

20 ml saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* age 18 years or older and * clinical signs and symptoms of meningoencephalitis or meningomyelitis and * cerebrospinal pleocytosis and * serological confirfmation of tick-borne encephalitis virus infection

Exclusion criteria

* pregnancy or * severe neurological impairment befor tick-borne encephalitis or * systemic corticosteroid treatment in the past 30 days or * allergy to corticosteroids or * immunosuppresive condition or therapy such as HIV with CD4 \< 200/ml, organ or bone marrow transplant, receiving chemotherapy, radiotherapy or any other immunosuppresive therapy, primary immunodeficiency, hematological maliganncy or * ventricular shunt or * endoscopically documented peptic gastric ulcer in the past six months or gastrointestinal bleeding with hemoglobin drop ≥ 20 units or * uncontrolled diabetes with hyperglicemia or * antiviral therapy with rilpivirin

Design outcomes

Primary

Measure	Time frame	Description
Modified Rankin Scale for Neurologic Disability	6 month follow-up visit	Proportion of patients with score 2 or higher on Modified Rankin Scale for Neurologic Disability, avilable at: https://www.mdcalc.com/calc/1890/modified-rankin-scale-neurologic-disability

Secondary

Measure	Time frame	Description
Incomplete outcome	at the 2, 6, and 12 month follow-up visits	Proportion of patients with objective sequelae and subjective symptoms post tick-borne encephalitis as detected by performing clinical examination (objective sequelae) and taking patient history (subjective symptoms)

Countries

Slovenia

Contacts

CONTACTDaša Stupica, MD, PhD

dasa.stupica@kclj.si+386 1 522 94 74

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026